Oral News and Research

RSS

Third-quarter 2009 financial results of Antigenics announced

Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.

29 Oct 2009

Perioperative oral dietary supplements before elective surgery offers no functional benefit

Blood glucose levels in a lot of patients fed normal liquid food (NLF) and a high calorie diet (HCD) were high. There was no significant difference in the blood prealbumin levels. There was a significant increase in the blood cortisol levels in some patients. The stress of surgery may be tolerated by children by feeding up to 2 h before elective surgery.

29 Oct 2009

Conceptus reports clinical success of its Essure non-incisional permanent birth control procedure

Conceptus, Inc., developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that the clinical success of the Essure® procedure will be highlighted at the 18th Annual Congress of the European Society for Gynaecological Endoscopy (ESGE) in Florence, Italy from October 28-31, 2009.

29 Oct 2009

Cempra Pharmaceuticals to present CEM-102 data at the Infectious Diseases Society of America meeting

Cempra Pharmaceuticals today announced data presentations of its lead antibiotic candidate, CEM-102 (fusidic acid), at the Infectious Diseases Society of America, 47th Annual Meeting, Oct. 29 to Nov. 1, 2009, in Philadelphia.

29 Oct 2009

Oral health-care tips for Halloween

It's that time of year again when kids look forward to indulging in candy and sweets - and parents begin to fret about the damage all that sugar does to their children's teeth. But the Ontario Dental Association (ODA) says that with a few simple oral health-care tips and practices, kids and parents alike can enjoy Halloween.

29 Oct 2009

Steroid-induced osteoporosis can now be treated with Teriparatide

A recent study determined glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, a synthetic form of the human parathyroid hormone. Researchers found patients with glucocorticoid-induced OP who were treated with teriparatide for 36 months had a greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate.

29 Oct 2009

Proper diet and exercise reduce risk of type 2 diabetes

Intensive lifestyle changes aimed at modest weight loss reduced the rate of developing type 2 diabetes by 34 percent over 10 years in people at high risk for the disease.

29 Oct 2009

No scientific proof that patients with Alzheimer's disease benefit from drugs containing the agent memantine

There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine. This is the conclusion in the final report that the Institute for Quality and Efficiency in Health Care (IQWiG) published in September 2009.

29 Oct 2009

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

28 Oct 2009

Simbionix launches advanced simulator for GI endoscopy and flexible bronchoscopy training

Simbionix, the world's leading developer of medical simulation systems, introduces it's new advanced simulator, the GI-BRONCH Mentor, a comprehensive solution for virtual reality training of GI Endoscopy and Flexible Bronchoscopy.

28 Oct 2009

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Elan Corporation, plc and Biogen Idec today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s disease during both induction and maintenance treatment.

28 Oct 2009

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Orexigen® Therapeutics, Inc. today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy.

28 Oct 2009

Data from Phase II clinical trial of NKTR-118 presented

Data from a phase II study demonstrated that oral NKTR-118 improved lower gastrointestinal dysfunction by increasing the frequency of bowel movements in patients with opioid-induced constipation, while simultaneously preserving opioid-mediated analgesia.

28 Oct 2009

Dementia patients face higher risk of flu mortality; refine guidelines needed for testing and vaccination policies

An epidemiological study on pneumonia and influenza (P&I) in adults age 65 and over reports that patients with dementia are diagnosed with flu less frequently, have shorter hospital stays, and have a fifty percent higher rate of death than those without dementia.

28 Oct 2009

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

NovaDel Pharma Inc., has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist® lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris.

28 Oct 2009

NCI grant to conduct innovative cancer research

A consortium led by The University of Texas Health Science Center at Houston has been awarded a major grant from the National Cancer Institute (NCI) to establish a center to conduct innovative cancer research.

28 Oct 2009

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.

27 Oct 2009

GI Dynamics’ EndoBarrier Gastrointestinal Liner for pre-surgical weight loss treatment demonstrates safety

GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced data which support the safety and efficacy of the EndoBarrier™ Gastrointestinal Liner for pre-surgical weight loss treatment, along with a positive effect on glucose homeostasis in morbidly obese patients with type 2 diabetes mellitus.

27 Oct 2009

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Alkermes, Inc. today announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetic effects of a single oral administration of five doses of ALKS 37 in approximately 40 healthy volunteers.

27 Oct 2009

Astellas enters into agreement with Medivation to develop MDV3100

Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.

27 Oct 2009

Oral News and Research

Third-quarter 2009 financial results of Antigenics announced

Perioperative oral dietary supplements before elective surgery offers no functional benefit

Conceptus reports clinical success of its Essure non-incisional permanent birth control procedure

Cempra Pharmaceuticals to present CEM-102 data at the Infectious Diseases Society of America meeting

Oral health-care tips for Halloween

Steroid-induced osteoporosis can now be treated with Teriparatide

Proper diet and exercise reduce risk of type 2 diabetes

No scientific proof that patients with Alzheimer's disease benefit from drugs containing the agent memantine

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Simbionix launches advanced simulator for GI endoscopy and flexible bronchoscopy training

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Data from Phase II clinical trial of NKTR-118 presented

Dementia patients face higher risk of flu mortality; refine guidelines needed for testing and vaccination policies

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

NCI grant to conduct innovative cancer research

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

GI Dynamics’ EndoBarrier Gastrointestinal Liner for pre-surgical weight loss treatment demonstrates safety

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Astellas enters into agreement with Medivation to develop MDV3100

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News